RET and non-small cell lung carcinoma: Genomic rearrangements of RET gene can form chimeric tyrosine kinase fusion proteins that often confer the constitutive oncogenic RET activation if the intact kinase domain is retained.[1]RET fusions occur in 1% to 2% of non-small cell lung cancers (NSCLC) and have been established as oncogenic drivers in this disease.[2]